Diagnosis and Treatment of Fungal Infections in Lung Transplant Recipients

Jesus E. Escamilla; Spenser E. January; Rodrigo Vazquez Guillamet

doi:10.3390/pathogens12050694

Diagnosis and Treatment of Fungal Infections in Lung Transplant Recipients

Jesus E. Escamilla, Spenser E. January, Rodrigo Vazquez Guillamet

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Fungal infections are a significant source of morbidity in the lung transplant population via direct allograft damage and predisposing patients to the development of chronic lung allograft dysfunction. Prompt diagnosis and treatment are imperative to limit allograft damage. This review article discusses incidence, risk factors, and symptoms with a specific focus on diagnostic and treatment strategies in the lung transplant population for fungal infections caused by Aspergillus, Candida, Coccidioides, Histoplasma, Blastomyces, Scedosporium/Lomentospora, Fusarium, and Pneumocystis jirovecii. Evidence for the use of newer triazole and inhaled antifungals to treat isolated pulmonary fungal infections in lung transplant recipients is also discussed.

Original language	English
Article number	694
Journal	Pathogens
Volume	12
Issue number	5
DOIs	https://doi.org/10.3390/pathogens12050694
State	Published - May 2023

Keywords

antifungals
fungal infections
lung transplant

Access to Document

10.3390/pathogens12050694

Cite this

@article{7a25351de1e14e319c0ff85e74925f5a,

title = "Diagnosis and Treatment of Fungal Infections in Lung Transplant Recipients",

abstract = "Fungal infections are a significant source of morbidity in the lung transplant population via direct allograft damage and predisposing patients to the development of chronic lung allograft dysfunction. Prompt diagnosis and treatment are imperative to limit allograft damage. This review article discusses incidence, risk factors, and symptoms with a specific focus on diagnostic and treatment strategies in the lung transplant population for fungal infections caused by Aspergillus, Candida, Coccidioides, Histoplasma, Blastomyces, Scedosporium/Lomentospora, Fusarium, and Pneumocystis jirovecii. Evidence for the use of newer triazole and inhaled antifungals to treat isolated pulmonary fungal infections in lung transplant recipients is also discussed.",

keywords = "antifungals, fungal infections, lung transplant",

author = "Escamilla, {Jesus E.} and January, {Spenser E.} and {Vazquez Guillamet}, Rodrigo",

note = "Funding Information: This article received no external funding. Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = may,

doi = "10.3390/pathogens12050694",

language = "English",

volume = "12",

journal = "Pathogens",

issn = "2076-0817",

number = "5",

}

TY - JOUR

T1 - Diagnosis and Treatment of Fungal Infections in Lung Transplant Recipients

AU - Escamilla, Jesus E.

AU - January, Spenser E.

AU - Vazquez Guillamet, Rodrigo

PY - 2023/5

Y1 - 2023/5

N2 - Fungal infections are a significant source of morbidity in the lung transplant population via direct allograft damage and predisposing patients to the development of chronic lung allograft dysfunction. Prompt diagnosis and treatment are imperative to limit allograft damage. This review article discusses incidence, risk factors, and symptoms with a specific focus on diagnostic and treatment strategies in the lung transplant population for fungal infections caused by Aspergillus, Candida, Coccidioides, Histoplasma, Blastomyces, Scedosporium/Lomentospora, Fusarium, and Pneumocystis jirovecii. Evidence for the use of newer triazole and inhaled antifungals to treat isolated pulmonary fungal infections in lung transplant recipients is also discussed.

AB - Fungal infections are a significant source of morbidity in the lung transplant population via direct allograft damage and predisposing patients to the development of chronic lung allograft dysfunction. Prompt diagnosis and treatment are imperative to limit allograft damage. This review article discusses incidence, risk factors, and symptoms with a specific focus on diagnostic and treatment strategies in the lung transplant population for fungal infections caused by Aspergillus, Candida, Coccidioides, Histoplasma, Blastomyces, Scedosporium/Lomentospora, Fusarium, and Pneumocystis jirovecii. Evidence for the use of newer triazole and inhaled antifungals to treat isolated pulmonary fungal infections in lung transplant recipients is also discussed.

KW - antifungals

KW - fungal infections

KW - lung transplant

UR - http://www.scopus.com/inward/record.url?scp=85160349310&partnerID=8YFLogxK

U2 - 10.3390/pathogens12050694

DO - 10.3390/pathogens12050694

M3 - Review article

C2 - 37242364

AN - SCOPUS:85160349310

SN - 2076-0817

VL - 12

JO - Pathogens

JF - Pathogens

IS - 5

M1 - 694

ER -

Diagnosis and Treatment of Fungal Infections in Lung Transplant Recipients

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this